C. Der
Molecular Biology · 2000–2021
A researcher in the Science corpus: 16 papers; trusts 13 researchers and is trusted by 7 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 200 citations into it; #5,965 of 17,773 by trust here, #4,510 by citations
- Oncology — 96 citations into it; #1,221 of 1,698 by trust here, #1,139 by citations
- Cancer Research — 67 citations into it
- Cell Biology — 51 citations into it
- Pulmonary and Respiratory Medicine — 18 citations into it
- Pathology and Forensic Medicine — 15 citations into it
- Genetics — 13 citations into it
- Immunology — 11 citations into it
Whom C. Der trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts C. Der overall
Papers from C. Der's perspective
Ordered by how strongly the researchers C. Der trusts endorse each paper. Same corpus, a different order for every researcher.
- Mutations of the BRAF gene in human cancer (Nature)
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses (Science)
- Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. (Cancer Cell)
- Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. (Genes & Development)
- Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
- The RAF proteins take centre stage (Nature reviews. Molecular cell biology)
- Whole genomes redefine the mutational landscape of pancreatic cancer (Nature)
- Rho GTPases in cell biology (Nature)
- RAS oncogenes: the first 30 years (Nature Reviews. Cancer)
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets (Nature Communications)
Their papers
- Ligand-dependent dynamics and intramolecular signaling in a PDZ domain. (2004) — 239 citations
- Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? (2010) — 800 citations
- Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 (2021) — 3,841 citations
- Drugging the undruggable Ras: mission possible? (2014) — 1,780 citations
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007) — 2,862 citations
- Understanding Ras: 'it ain't over 'til it's over'. (2000) — 821 citations
- The Ras superfamily at a glance (2005) — 1,557 citations
- Rho-family GTPases: it's not only Rac and Rho (and I like it) (2004) — 662 citations
- GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors (2005) — 1,867 citations
- RAS isoforms and mutations in cancer at a glance (2016) — 836 citations
- KRAS: feeding pancreatic cancer proliferation (2014) — 622 citations
- KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018) — 742 citations
- Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 (2016) — 1,523 citations
- A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma (2010) — 224 citations
- Faculty Opinions recommendation of Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. (2008) — 595 citations
- Activation of Phospholipase C-ε by Heterotrimeric G Protein βγ-Subunits* (2001) — 104 citations